Payment overview · 2025
General Payments
$1,112.37
39 reported records · 7 companies
Healthcare provider profile · identity verified
Wendy A Griffith-Reece, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD GARDENS, NY · NPI 1114032521
Verified facts
What the public records show
CMS Open Payments records show Wendy A Griffith-Reece, MD received $1,112.37 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $568.76 | 51.1% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $257.31 | 23.1% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.54 | 10.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.52 | 5.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.91 | 5.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.35 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.98 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,112.37 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $431.57 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $257.31 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $135.11 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $112.54 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.77 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.42 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.52 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.52 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.91 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 187 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 324 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
187 | 50 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
112 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
324 | 80 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
324 | 80 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 757 | 216 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 587 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 423 | 132 |
| Gabapentin | Gabapentin | 376 | 100 |
| Losartan Potassium | Losartan Potassium | 339 | 103 |
| Jardiance | Empagliflozin | 324 | 80 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 314 | 112 |
| Metformin Hcl | Metformin Hcl | 295 | 94 |
| Fluticasone Propionate | Fluticasone Propionate | 249 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 72 |
| Omeprazole | Omeprazole | 213 | 71 |
| Farxiga | Dapagliflozin Propanediol | 187 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 61 |
| Furosemide | Furosemide | 176 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 59 |
| Alendronate Sodium | Alendronate Sodium | 165 | 45 |
| Donepezil Hcl | Donepezil Hcl | 158 | 53 |
| Lisinopril | Lisinopril | 158 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 28 |
| Ezetimibe | Ezetimibe | 112 | 41 |
| Kerendia | Finerenone | 112 | 30 |
| Ozempic | Semaglutide | 112 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 30 |
| Januvia | Sitagliptin Phosphate | 108 | 28 |
| Potassium Chloride | Potassium Chloride | 107 | 35 |
| Calcitriol | Calcitriol | 106 | 35 |
| Allopurinol | Allopurinol | 105 | 30 |
| Montelukast Sodium | Montelukast Sodium | 104 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 34 |
| Rybelsus | Semaglutide | 98 | 23 |
| Ramipril | Ramipril | 95 | 35 |
| Enalapril Maleate | Enalapril Maleate | 94 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 23 |
| Famotidine | Famotidine | 82 | 30 |
| Naproxen | Naproxen | 80 | 26 |
| Mometasone Furoate | Mometasone Furoate | 78 | 20 |
| Trazodone Hcl | Trazodone Hcl | 78 | 30 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 75 | 18 |
| Folic Acid | Folic Acid | 75 | 24 |
| Ammonium Lactate | Ammonium Lactate | 71 | 21 |
| Carvedilol | Carvedilol | 71 | 23 |
| Glimepiride | Glimepiride | 71 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 19 |
| Nifedipine Er | Nifedipine | 70 | 24 |
| Azithromycin | Azithromycin | 62 | 49 |
| Nateglinide | Nateglinide | 61 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 59 | 14 |
| Glipizide | Glipizide | 59 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 58 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 17 |
| Terconazole | Terconazole | 57 | 26 |
| Simvastatin | Simvastatin | 56 | 24 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 54 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 16 |
| Ibuprofen | Ibuprofen | 54 | 21 |
| Valsartan | Valsartan | 53 | 19 |
| Lidocaine | Lidocaine | 49 | 11 |
| Atenolol | Atenolol | 47 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 16 |
| Risedronate Sodium | Risedronate Sodium | 40 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 20 |
| Eliquis | Apixaban | 36 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lactulose | Lactulose | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 15 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 30 |
| Prednisone | Prednisone | 33 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 32 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | 14 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 11 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,112.37 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, VOQUEZNA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error